JP3504365B2 - Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent - Google Patents

Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent

Info

Publication number
JP3504365B2
JP3504365B2 JP03604295A JP3604295A JP3504365B2 JP 3504365 B2 JP3504365 B2 JP 3504365B2 JP 03604295 A JP03604295 A JP 03604295A JP 3604295 A JP3604295 A JP 3604295A JP 3504365 B2 JP3504365 B2 JP 3504365B2
Authority
JP
Japan
Prior art keywords
microorganism
mixture
freeze
genus
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP03604295A
Other languages
Japanese (ja)
Other versions
JPH08205857A (en
Inventor
誠一 島村
憲雄 石橋
文明 阿部
小百合 宮浦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morinaga Milk Industry Co Ltd
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Priority to JP03604295A priority Critical patent/JP3504365B2/en
Publication of JPH08205857A publication Critical patent/JPH08205857A/en
Application granted granted Critical
Publication of JP3504365B2 publication Critical patent/JP3504365B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、凍結融解時及び凍結乾
燥時の微生物の損傷及び死滅が少なく、かつ高い生残性
を有する凍結又は凍結乾燥微生物菌体の製造法に関する
ものである。更に詳しくは、本発明は、微生物の菌体分
散液に、アスパラギン酸、アルギニン、グルタミン酸、
プロリン、リジン、ロイシン及びメチオニンからなる特
定のアミノ酸群より選択される少くとも3種のアミノ酸
の混合物又はそれらの誘導体の混合物を含有してなる微
生物保護剤、及び当該アミノ酸の混合物又はそれらの誘
導体をアミノ酸の総量として少なくとも0.5%(重
量)の濃度で添加して混合し、凍結又は凍結乾燥するこ
とを特徴とする凍結又は凍結乾燥微生物菌体の製造法、
である。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a process for producing a frozen or freeze-dried microbial cell which has less damage and death of a microorganism during freeze-thawing and freeze-drying and has high survival property. More specifically, the present invention relates to a bacterial cell dispersion liquid of a microorganism, aspartic acid, arginine, glutamic acid,
A microbial protective agent containing a mixture of at least three amino acids selected from a specific amino acid group consisting of proline, lysine, leucine and methionine or a derivative thereof, and a mixture of the amino acids or their derivatives A method for producing a frozen or lyophilized microbial cell, which comprises adding at a concentration of at least 0.5% (by weight) as a total amount of amino acids, mixing, and freezing or lyophilizing;
Is.

【0002】本明細書において百分率は、微生物の生残
率を除き、特に断りのない限り重量による値であり、ビ
フィドバクテリウム(Bifidobacterium)属に属する微生
物をビフィズス菌、ビフィズス菌以外の乳酸菌を乳酸菌
等、ビフィズス菌及び乳酸菌等をまとめて乳酸菌類、微
生物の細胞又は菌体をまとめて菌体と記載することがあ
る。
In the present specification, the percentage is a value by weight, excluding the survival rate of microorganisms, unless otherwise specified. Bifidobacterium is a microorganism belonging to the genus Bifidobacterium and lactic acid bacteria other than Bifidobacterium are lactic acid bacteria. Lactic acid bacteria, etc., bifidobacteria, lactic acid bacteria, etc. may be collectively referred to as lactic acid bacteria, and cells or cells of microorganisms may be collectively referred to as bacterial cells.

【0003】[0003]

【従来の技術】乳酸菌類は有用な腸内細菌の一つとして
広く知られており、特にビフィズス菌の生理学的意義に
ついては多数の報告があり、腸内において、乳酸、酢酸
等の有機酸を生産し、かつ有害菌の増殖を抑制する作
用、ビタミンの産生、免疫力の賦活化等が明らかにされ
ている(光岡知足編著、「ビフィズス菌の研究」、財団
法人日本ビフィズス菌センター、1994年)。
BACKGROUND OF THE INVENTION Lactic acid bacteria are widely known as one of the useful enterobacteria, and there are many reports on the physiological significance of Bifidobacteria. In the intestine, organic acids such as lactic acid and acetic acid were detected. The effects of producing and suppressing the growth of harmful bacteria, production of vitamins, activation of immunity, etc. have been clarified (Mitsuoka Tomohushi, "Research on Bifidobacteria", Japan Bifidobacteria Center, 1994). ).

【0004】そのため、ビフィズス菌を摂取することに
より健康を維持することを目的として、ヨ−グルト、菓
子類、飲料類等のビフィズス菌を含有する種々の食品が
開発されている(光岡知足編著、「ビフィズス菌の研
究」、財団法人日本ビフィズス菌センター、1994
年)。これらの食品にビフィズス菌を添加する場合、予
め培養したビフィズス菌を、加工して添加するが、その
加工には大きな労力及び時間を要し、かつ加工工程にお
いてビフィズス菌の高い生残率を維持するためには、技
術的に極めて困難な点があった。
Therefore, various foods containing bifidobacteria, such as yogurt, confectionery, and beverages, have been developed for the purpose of maintaining health by ingesting bifidobacteria (edited by Chizu Mitsuoka, "Research on Bifidobacteria", Japan Bifidobacteria Center, 1994
Year). When adding Bifidobacteria to these foods, pre-cultured Bifidobacteria are processed and added, but the processing requires a large amount of labor and time, and a high survival rate of Bifidobacteria is maintained in the processing process. In order to do so, there were technically extremely difficult points.

【0005】一方、乳酸菌は、古くからヨ−グルト、チ
−ズ等極めて多数の乳製品にスタ−タ−として利用され
ており、また近年では、ビフィズス菌と同様に、その整
腸作用を期待することにより多くの食品に乳酸菌が添加
されている(微生物、第16巻、第44〜55ページ、
1990年)。従来、これらの乳酸菌等は、牛乳等で培
養することによりその菌体を取得しているが、そのため
に多くの労力と時間を必要とし、また菌株の品質管理等
についても十分に注意をしなければならないという問題
があった。
On the other hand, lactic acid bacteria have been used as a starter for a very large number of dairy products such as yogurt and cheese since ancient times, and in recent years, like the bifidobacteria, they are expected to have an intestinal regulating action. By doing so, lactic acid bacteria are added to many foods (microorganisms, vol. 16, pages 44-55,
1990). Conventionally, these lactic acid bacteria, etc. are obtained by culturing them in milk etc., but this requires a lot of labor and time, and sufficient attention must be paid to the quality control of the strains. There was a problem that it had to be.

【0006】従って、予め凍結若しくは凍結乾燥したビ
フィズス菌又は乳酸菌生菌体を使用することにより、ビ
フィズス菌又は乳酸菌を含有する食品、例えば、ヨ−グ
ルト、チ−ズ等の乳製品が簡単に製造することが可能と
なる。しかしながら、これらの製品に必要な生菌濃度を
有する凍結又は凍結乾燥乳酸菌類を製造することは、凍
結融解時又は凍結乾燥時において、菌体が被る損傷及び
/又は死滅を防止しなければならないという大きな問題
があった。
[0006] Therefore, foods containing bifidobacteria or lactic acid bacteria, such as dairy products such as yogurt and cheese, can be easily produced by using bifidobacterium or lactic acid bacteria viable cells that have been previously frozen or lyophilized. It becomes possible to do. However, the production of frozen or freeze-dried lactic acid bacteria having the required viable cell concentration for these products must prevent damage and / or death of the cells during freeze-thawing or freeze-drying. There was a big problem.

【0007】従来、これらの問題を解決するために、多
くの凍結保護物質及び凍結乾燥保護物質が開発された。
これらの物質には、脱脂乳、グルタミン酸ナトリウム、
ゼラチン及びしょ糖(特公昭53−8793号公報)、
フェニルアラニン、ヒスチジン、クエン酸、コハク酸、
酒石酸及び炭酸アルカリ(特開昭61−265085号
公報)等が知られており、その他に、例えば、アミノ酸
単独、アミノ酸とアミノ酸以外の物質との組み合わせ、
ペプトン、グルコ−ス、トレハロ−ス、脱脂粉乳、アス
コルビン酸ソ−ダ−等も検討されている[クライオバイ
オロジー(Cryobiology)、第26巻、第149〜153
ページ、1989年]。
In the past, many cryoprotectants and freeze-dried protectants have been developed to solve these problems.
These substances include skim milk, sodium glutamate,
Gelatin and sucrose (Japanese Patent Publication No. 53-8793),
Phenylalanine, histidine, citric acid, succinic acid,
Tartaric acid and alkali carbonate (JP-A-61-265085) are known, and in addition, for example, amino acids alone, combinations of amino acids and substances other than amino acids,
Peptone, glucose, trehaloose, skimmed milk powder, ascorbic acid soda, etc. are also being investigated [Cryobiology, Vol. 26, 149-153.
Page, 1989].

【0008】しかしながら、これらの従来技術によって
も凍結又は凍結乾燥時の菌体の損傷又は死滅は甚大であ
り、高い生菌濃度で、かつ安定した凍結菌体又は凍結乾
燥菌体を製造することは困難であった。また、凍結融解
と凍結乾燥とでは菌体が被る損傷又は死滅の機構が異な
り、そのため、凍結乾燥に対する有効な保護剤が、必ず
しも凍結融解に対する保護剤とはなり得ないという問題
があった。また、逆に、凍結融解に対する有効な保護剤
が、必ずしも凍結乾燥に対する有効な保護剤とはなり得
ず、凍結菌体又は凍結乾燥菌体調製のためには、それぞ
れ別個の保護剤を検索しなければならないという不都合
があった。
However, even with these conventional techniques, the damage or death of the cells during freezing or freeze-drying is great, and it is not possible to produce stable frozen cells or freeze-dried cells with a high viable cell concentration. It was difficult. In addition, there is a problem that freeze-thawing and freeze-drying have different mechanisms of damage or death of cells, and therefore an effective protective agent for freeze-drying cannot necessarily be a protective agent for freeze-thawing. On the contrary, an effective protectant against freeze-thawing may not necessarily be an effective protectant against freeze-drying, and for the preparation of frozen cells or freeze-dried cells, individual protective agents should be searched. There was the inconvenience of having to.

【0009】更に、凍結又は凍結乾燥菌体の製造工程に
おいては、菌体分散液を凍結する速度が菌体の損傷又は
死滅に対して甚大な影響を与えるので、工業的に凍結又
は凍結乾燥菌体を製造する場合には、凍結速度を調節す
る上で克服しなければならない問題点が多数存在した。
以上のように、従来、微生物保護剤として各種のものが
開発されているが、アミノ酸混合物については、全く知
られておらず、また、微生物の凍結又は凍結乾燥工程に
おいて微生物菌体の損傷又は死滅を防止し得る汎用保護
剤は存在せず、その開発が待望されていた。
Furthermore, in the process of producing frozen or freeze-dried cells, the rate of freezing the cell dispersion has a great influence on the damage or death of the cells, so that the freeze- or freeze-dried cells are industrially used. When manufacturing the body, there were many problems that had to be overcome in controlling the freezing rate.
As described above, various types of microbial protective agents have been developed so far, but amino acid mixtures are not known at all, and microbial cells are damaged or killed in the process of freezing or freeze-drying the microorganisms. There is no general-purpose protective agent that can prevent the above-mentioned problems, and its development has been long awaited.

【0010】[0010]

【発明が解決しようとする課題】本発明者らは、前記従
来技術に鑑みて、微生物の凍結及び凍結乾燥工程におい
て微生物菌体の損傷又は死滅を防止し得る汎用保護剤に
ついて鋭意研究を行った結果、可及的速やかに液温を低
下させる急速凍結と、徐々に液温を低下させる緩慢凍結
とでは、生成する氷の結晶構造の相違から、微生物菌体
に対して異なった損傷を与えるため、凍結速度に適した
凍結保護剤を選択しなければならないこと、及びアミノ
酸の中には凍結又は凍結乾燥により微生物菌体に損傷を
与えるアミノ酸が存在すること、及び微生物菌体に損傷
を与えるアミノ酸以外の特定のアミノ酸混合物が、微生
物の凍結又は凍結乾燥工程において微生物菌体の損傷又
は死滅を防止し得ることを見い出し、本発明を完成し
た。
In view of the above-mentioned prior art, the present inventors have conducted earnest research on a general-purpose protective agent capable of preventing damage or death of microbial cells in the steps of freezing and lyophilizing microorganisms. As a result, rapid freezing, which lowers the liquid temperature as quickly as possible, and slow freezing, which gradually lowers the liquid temperature, cause different damage to microbial cells due to the difference in the crystal structure of the ice produced. , It is necessary to select a cryoprotective agent suitable for the freezing rate, and there are amino acids that damage microbial cells by freezing or freeze-drying, and amino acids that damage microbial cells. It was found that a specific amino acid mixture other than the above can prevent the damage or death of microbial cells in the process of freezing or freeze-drying the microorganism, and completed the present invention.

【0011】本発明の目的は、凍結又は凍結乾燥時の微
生物菌体の損傷又は死滅が少なく、かつ生残率の高い凍
結又は凍結乾燥微生物菌体を得ることが可能な微生物保
護剤を提供することである。
An object of the present invention is to provide a microbial protectant capable of obtaining a frozen or lyophilized microbial cell having a high survival rate with less damage or death of the microbial cell during freezing or lyophilization. That is.

【0012】本発明の他の目的は、凍結又は凍結乾燥工
程において微生物菌体の損傷又は死滅が少なく、かつ生
残率の高い凍結又は凍結乾燥微生物菌体の製造方法を提
供することである。
[0012] Another object of the present invention is to provide a method for producing a frozen or freeze-dried microbial cell which is less likely to be damaged or killed in the freezing or freeze-drying step and has a high survival rate.

【0013】[0013]

【課題を解決するための手段】前記課題を解決する本発
明の第1の発明は、微生物を凍結又は凍結乾燥時の損傷
から保護する組成物であって、アスパラギン酸、アルギ
ニン、グルタミン酸、プロリン、リジン、ロイシン及び
メチオニンからなる特定のアミノ酸群より選択される少
くとも3種のアミノ酸の混合物又はそれらの誘導体の混
合物からなることを特徴とする微生物保護剤、であり、
3種のアミノ酸の混合物が、アスパラギン酸、グルタミ
ン酸及びリジンの混合物であること、3種のアミノ酸誘
導体の混合物が、アスパラギン酸ナトリウム、グルタミ
ン酸ナトリウム及びリジン塩酸塩の等量混合物であるこ
と、及び微生物が、ビフィドバクテリウム(Bifidobact
erium)属に属する微生物又はラクトバシラス(Lactobac
illus)属に属する微生物、ストレプトコッカス(Strepto
coccus)属に属する微生物、ラクトコッカス(Lactococcu
s) 属に属する微生物、エンテロコッカス(Enterococcu
s)属に属する微生物又はこれらの混合微生物であるこ
と、を望ましい態様としてもいる。
The first invention of the present invention for solving the above problems is a composition for protecting microorganisms from damage during freezing or lyophilization, which comprises aspartic acid, arginine, glutamic acid, proline, lysine, a microorganism protection agent, characterized by comprising a mixture or mixtures of their derivatives of at least three amino acids selected from a specific group of amino acids consisting of leucine and methionine,
The mixture of three amino acids is a mixture of aspartic acid, glutamic acid and lysine, the mixture of three amino acid derivatives is an equal mixture of sodium aspartate, sodium glutamate and lysine hydrochloride, and the microorganism is , Bifidobact
erium) microorganisms or Lactobacillus
illus), a microorganism belonging to the genus Strepto
Lactococcu, a microorganism belonging to the genus coccus
s) Enterococcus, a microorganism belonging to the genus
s) a microorganism belonging to the genus or a mixed microorganism thereof is also a preferred embodiment.

【0014】 前記課題を解決する本発明の第2の発明
は、洗浄した湿菌体を水に分散した微生物の菌体分散液
に、アスパラギン酸、アルギニン、グルタミン酸、プロ
リン、リジン、ロイシン及びメチオニンからなる特定の
アミノ酸群より選択される少くとも3種のアミノ酸の混
合物又はそれらの誘導体の混合物を、アミノ酸の総量と
して少なくとも0.5%(重量)の濃度で添加して混合
し、凍結又は凍結乾燥することを特徴とする凍結又は凍
結乾燥微生物の製造法、であり、アミノ酸の総量が、2
〜20%(重量)であること、3種のアミノ酸の混合物
が、アスパラギン酸、グルタミン酸及びリジンの混合物
であること、3種のアミノ酸誘導体の混合物が、アスパ
ラギン酸ナトリウム、グルタミン酸ナトリウム及びリジ
ン塩酸塩の等量混合物であること、及び微生物が、ビフ
ィドバクテリウム(Bifidobacterium)属に属する微生物
又はラクトバシラス(Lactobacillus)属に属する微生
物、ストレプトコッカス(Streptococcus)属に属する微
生物、ラクトコッカス(Lactococcus) 属に属する微生
物、エンテロコッカス(Enterococcus)属に属する微生物
又はこれらの混合微生物であること、を望ましい態様と
してもいる。
A second aspect of the present invention for solving the above-mentioned problems is to provide a bacterial cell dispersion of a microorganism in which washed wet bacterial cells are dispersed in water, wherein aspartic acid, arginine, glutamic acid, proline, lysine, leucine and methionine are added. A mixture of at least three amino acids selected from the following specific amino acid group or a mixture of derivatives thereof is added at a concentration of at least 0.5% (by weight) as the total amount of amino acids, mixed, and then freeze-dried or freeze-dried. A method for producing a frozen or freeze-dried microorganism, characterized in that the total amount of amino acids is 2
˜20% (by weight), the mixture of three amino acids is a mixture of aspartic acid, glutamic acid and lysine, and the mixture of three amino acid derivatives is a mixture of sodium aspartate, sodium glutamate and lysine hydrochloride. Equivalent mixture, and the microorganisms are microorganisms belonging to the genus Bifidobacterium (Bifidobacterium) or Lactobacillus (Lactobacillus), microorganisms belonging to the genus Streptococcus, microorganisms belonging to the genus Lactococcus The microorganism is a microorganism belonging to the genus Enterococcus or a mixed microorganism thereof, which is also a preferable embodiment.

【0015】次に、本発明について詳述する。最初に、
本発明の第1の発明について説明する。本発明の微生物
保護剤の適用の対象となる微生物は、凍結又は凍結乾燥
して使用される有用な微生物であり、その種類は、特に
限定されるものではないが、具体的には、例えば、ビフ
ィズス菌、乳酸菌等、細菌、黴、酵母等である。より具
体的には、ビフィズス菌は、ビフィドバクテリウム(Bi
fidobacterium)属に属する微生物であり、例えば、ビフ
ィドバクテリウム・ロングム(Bifidobacterium longu
m), ビフィドバクテリウム・インファンチス(Bifidob
acterium infantis)、ビフィドバクテリウム・アドレ
ッセンティス(Bifidobacterium adolescentis)、ビフ
ィドバクテリウム・ブレ−ベ(Bifidobacterium breve)
等であり、いずれも市販されているか又は寄託機関から
容易に入手することができる菌株である。
Next, the present invention will be described in detail. At first,
The first aspect of the present invention will be described. Microorganisms to which the microbial protectant of the present invention is applied are useful microorganisms that are frozen or lyophilized and used, and the type thereof is not particularly limited, but specifically, for example, Bifidobacteria, lactic acid bacteria, etc., bacteria, mold, yeast, etc. More specifically, Bifidobacteria are Bifidobacterium (Bi
A microorganism belonging to the genus fidobacterium, for example, Bifidobacterium longu
m), Bifidob
acterium infantis), Bifidobacterium adolescentis, Bifidobacterium breve
And the like, and all of them are strains that are commercially available or can be easily obtained from depository institutions.

【0016】また、乳酸菌等は、一般に乳酸菌に分類さ
れている微生物であり、例えば、ラクトバシラス(Lact
obacillus)属に属する微生物[例えば、ラクトバシラス
・アシドフィルス(Lactobacillus acidophilus)、ラク
トバシラス・ブルガリカス(Lactobacillus bulgaricu
s)、ラクトバチラス・カゼイ(Lactobacillus casei)
等]、ストレプトコッカス属に属する微生物[例えば、
ストレプトコッカス・サ−モフィルス(Streptococcus
thermophilus)等]、ラクトコッカス属に属する微生物
[例えば、ラクトコッカス・ラクティス(Lactococcus
lactis)等]、エンテロコッカス属に属する微生物[例
えば、エンテロコッカス・フェシウム(Enterococcus f
aecium)、エンテロコッカス・フェカ−リス(Enteroco
ccus faecalis)等]等であり、いずれも市販されている
か又は寄託機関から容易に入手することができる菌株で
ある。
Lactic acid bacteria and the like are microorganisms generally classified as lactic acid bacteria. For example, Lactobacillus (Lactobacillus)
microorganisms belonging to the genus obacillus [eg, Lactobacillus acidophilus, Lactobacillus bulgaricu
s), Lactobacillus casei)
Etc.], a microorganism belonging to the genus Streptococcus [eg,
Streptococcus
thermophilus), etc.], a microorganism belonging to the genus Lactococcus [eg, Lactococcus lactis (Lactococcus
lactis), etc.], a microorganism belonging to the genus Enterococcus [eg, Enterococcus faecium (Enterococcus f
aecium), Enterococcus faecalis (Enteroco)
ccus faecalis) etc.] and the like, all of which are commercially available strains or can be easily obtained from depository institutions.

【0017】また、乳酸菌類以外の細菌としては、バシ
ラス(Bacillus)属に属する微生物[例えば、バシラス・
サチリス(Bacillus subtilis) 等]等であり、黴は、ペ
ニシリウム(Penicillium) 属に属する微生物[例えば、
ペニシリウム・ロックフォルチ(Penicillium roquefort
i)等]等であり、酵母は、サッカロミセス(Saccharomyc
es) 属に属する微生物[例えば、サッカロミセス・セレ
ビシエ(Saccharomyces cerevisiae)等]等であり、いず
れも市販されているか又は寄託機関から容易に入手する
ことができる菌株である。
Further, as bacteria other than lactic acid bacteria, microorganisms belonging to the genus Bacillus [eg, Bacillus
Bacillus subtilis etc.] and the like, and the mold is a microorganism belonging to the genus Penicillium [eg,
Penicillium roquefort
i) etc.] etc., and yeast is Saccharomyces (Saccharomyc
es) microorganisms belonging to the genus [eg, Saccharomyces cerevisiae, etc.] and the like, all of which are commercially available strains or can be easily obtained from depository institutions.

【0018】本発明の微生物保護剤を構成するアミノ酸
は、アスパラギン酸、アルギニン、グルタミン酸、プロ
リン、リジン、ロイシン及びメチオニンからなる特定の
アミノ酸群より選択される少くとも3種の任意のアミノ
酸の混合物又はそれらの誘導体の混合物であり、4種以
上の混合物であってもよいが、望ましくは、アスパラギ
ン酸、グルタミン酸及びリジンの混合物、特に望ましく
は、アスパラギン酸ナトリウム、グルタミン酸ナトリウ
ム及びリジン塩酸塩の混合物、であり、アミノ酸は、L
型、D型又はDL型のいずれの光学異性体であってもよ
い。混合する3種乃至それ以上のアミノ酸の割合は、任
意であるが、等量混合物が特に望ましく、また、アミノ
酸の誘導体としては、ナトリウム塩、塩酸塩、カリウム
塩、その他の塩類、水和物等を好適なものとして例示す
ることができる。
The amino acid constituting the microbial protectant of the present invention is a mixture of at least three kinds of amino acids selected from a specific amino acid group consisting of aspartic acid, arginine, glutamic acid, proline, lysine, leucine and methionine, or A mixture of these derivatives, which may be a mixture of four or more, is preferably a mixture of aspartic acid, glutamic acid and lysine, particularly preferably a mixture of sodium aspartate, sodium glutamate and lysine hydrochloride. Yes, the amino acid is L
It may be any type, D type or DL type optical isomer. The ratio of the three or more kinds of amino acids to be mixed is arbitrary, but an equivalent mixture is particularly preferable, and as the amino acid derivative, sodium salt, hydrochloride, potassium salt, other salts, hydrate, etc. Can be illustrated as a suitable example.

【0019】混合するアミノ酸又はその誘導体は、後記
する試験例から明らかなように、その混合する数が多い
程微生物の生残率が向上するが、価格との関係等から、
例えば、3〜7種類の範囲で適宜組み合わせることが好
適なものとして例示できる。本発明の微生物保護剤に使
用するアミノ酸及びアミノ酸誘導体は市販品を用いるこ
とが可能であり、また、本発明の微生物保護剤は、適当
な量(例えば、1kg単位等)を公知の方法で密封包装
して、最終製品とすることができる。以上のとおりの構
成を有する本発明の微生物保護剤は、凍結又は凍結乾燥
工程において損傷又は死滅が少なく、かつ高い生残率を
有する微生物の凍結菌体又は凍結乾燥菌体が得られるこ
とを可能とするものであり、急速凍結、緩慢凍結等の凍
結速度に無関係に、高い生残率を有する微生物の凍結菌
体又は凍結乾燥菌体が得られるという効果を有する。
As will be apparent from the test examples described below, the larger the number of mixed amino acids or their derivatives, the higher the survival rate of microorganisms.
For example, it is possible to exemplify a suitable combination in the range of 3 to 7 types. Commercially available amino acids and amino acid derivatives used in the microbial protection agent of the present invention can be used, and the microbial protection agent of the present invention is sealed in an appropriate amount (eg, 1 kg unit) by a known method. It can be packaged into a final product. The microbial protectant of the present invention having the above-mentioned constitution makes it possible to obtain frozen cells or freeze-dried cells of a microorganism having less damage or death in the freezing or freeze-drying step and having a high survival rate. Therefore, it has an effect that frozen or freeze-dried cells of a microorganism having a high survival rate can be obtained regardless of the freezing rate such as quick freezing and slow freezing.

【0020】更に、本発明の微生物保護剤は、アミノ酸
又はその誘導体のみから構成することができるので、公
知の保護剤にはない分散性、溶解性、溶解後の安定性等
に優れた効果も有している。尚、必要に応じて本発明の
微生物保護剤と公知の保護剤とを併用すること、他の任
意の成分を適宜配合することもできる。
Furthermore, since the microbial protectant of the present invention can be composed only of amino acids or derivatives thereof, it also has excellent effects such as dispersibility, solubility and stability after dissolution, which are not found in known protectants. Have If necessary, the microorganism protecting agent of the present invention may be used in combination with a known protecting agent, and other optional components may be appropriately blended.

【0021】次に、本発明の第2の発明について説明す
る。本発明の凍結又は凍結乾燥微生物の製造法において
は、最初に微生物の菌体を常法により製造する。微生物
を増殖させるために必要な培地は、微生物により異なる
が、例えば、グルコ−ス、酵母エキス、ペプトン等を含
む液体培地に、乳酸菌類の1種又は2種以上を接種し、
通常25〜45℃で4〜24時間培養し、培養液から菌
体を集菌し、洗浄し、湿菌体を得ることができる。
Next, the second invention of the present invention will be described. In the method for producing a frozen or freeze-dried microorganism of the present invention, first, bacterial cells of the microorganism are produced by a conventional method. The medium necessary for growing the microorganism varies depending on the microorganism, but for example, a liquid medium containing glucose, yeast extract, peptone or the like is inoculated with one or more kinds of lactic acid bacteria,
Usually, the cells can be cultured at 25 to 45 ° C. for 4 to 24 hours, and the bacterial cells are collected from the culture solution and washed to obtain wet bacterial cells.

【0022】本発明の方法においては、前記のとおり得
られた湿菌体を、通常0.5〜12%の濃度(菌体の保
存、菌体の大量生産等の目的により湿菌体の分散濃度は
異なる)で水に分散し、微生物の菌体分散液を調製す
る。次いで、当該、菌体分散液に、前記微生物保護剤
を、アミノ酸の総量として、少なくとも0.5%の濃度
で添加して均一に混合する。添加するアミノ酸混合物の
総量は、0.5〜30%、望ましくは2〜20%、であ
る。前記微生物菌体の分散濃度範囲では、当該アミノ酸
混合物の添加濃度は、微生物菌体の分散濃度には無関係
であり、微生物菌体分散液中の濃度によって保護効果が
奏せられる。この時、当該微生物保護剤以外の公知の凍
結保護剤(例えば、グリセリン、ショ糖、アスコルビン
酸等)を併用することもできる。この混合液のpHが酸
性である場合には、水酸化ナトリウム、炭酸ナトリウ
ム、水酸化カリウム等のpH調整剤により、ほぼ中性、
望ましくは6〜8にpHを調整する。
In the method of the present invention, the wet bacterial cells obtained as described above are usually dispersed at a concentration of 0.5 to 12% (for the purpose of preserving the bacterial cells, mass-producing the bacterial cells, etc.). Disperse in water at different concentrations) to prepare a microbial cell dispersion. Next, the microorganism-protecting agent is added to the bacterial cell dispersion liquid at a concentration of at least 0.5% as the total amount of amino acids and uniformly mixed. The total amount of amino acid mixture added is 0.5-30%, preferably 2-20%. In the microbial cell dispersion concentration range, the added concentration of the amino acid mixture is irrelevant to the microbial cell dispersion concentration, and the protective effect is exerted by the concentration in the microbial cell dispersion liquid. At this time, a known cryoprotective agent other than the microorganism protection agent (for example, glycerin, sucrose, ascorbic acid, etc.) can be used in combination. When the pH of this mixed solution is acidic, a pH adjuster such as sodium hydroxide, sodium carbonate, potassium hydroxide, etc.
The pH is preferably adjusted to 6-8.

【0023】次に、本発明の方法においては、当該微生
物保護剤を添加し、混合した混合液を、常法により凍結
又は凍結乾燥を行うが、凍結する場合は、例えば、−2
0℃〜−160℃以下(例えば、液体窒素の使用等)で
実施し、凍結乾燥する場合は、例えば、棚温度35℃以
下、真空度50〜400hPa程度の真空下で、公知の
方法により行うことができる。
Next, in the method of the present invention, the mixed solution to which the microorganism protecting agent is added and mixed is frozen or lyophilized by a conventional method.
When it is carried out at 0 ° C to -160 ° C or lower (for example, use of liquid nitrogen) and freeze-dried, for example, it is performed by a known method under a vacuum at a shelf temperature of 35 ° C or lower and a vacuum degree of about 50 to 400 hPa. be able to.

【0024】本発明の方法においては、以上のように当
該微生物保護剤を添加し、混合することにより凍結又は
凍結乾燥時の微生物の損傷又は死滅を軽減し、かつ高い
生残率で高濃度の微生物の凍結菌体又は凍結乾燥菌体を
得ることができる。また、本発明の方法においては、必
要に応じて本発明の微生物保護剤と公知の保護剤とを併
用すること、他の任意の成分を適宜配合することもでき
る。
In the method of the present invention, by adding and mixing the microorganism protecting agent as described above, damage or death of microorganisms during freezing or freeze-drying is reduced, and a high survival rate and a high concentration are obtained. Frozen cells or freeze-dried cells of microorganisms can be obtained. Further, in the method of the present invention, the microbial protective agent of the present invention may be used in combination with a known protective agent, if desired, and other optional components may be appropriately blended.

【0025】次に、試験例を示して本発明を詳述する。 試験例1 この試験は、急速凍結及び緩慢凍結の2種の凍結速度に
おける凍結融解時の各アミノ酸又はそれらの誘導体の乳
酸菌類菌体に対する保護効果を調べるために行った。 1)湿菌体の調製 ペプトン(ディフコ社製)1%、酵母エキス(ディフコ
社製)2%、グルコ−ス(ディフコ社製)3%、リン酸
1水素2ナトリウム(和光純薬工業社製)0.5%、リ
ン酸2水素1ナトリウム(和光純薬工業社製)0.5%
を含む液体培地(pH6.5)に、ラクトバシラス・ブ
ルガリカス(Lactobacillus bulgaricus)ATCC11
842(ATCCから入手)を接種し、37℃で12時
間培養した。培養終了後、培養液から菌体を集菌し、水
で洗浄し、再び集菌し、乳酸菌の湿菌体を得た。
Next, the present invention will be described in detail by showing test examples. Test Example 1 This test was conducted in order to examine the protective effect of each amino acid or a derivative thereof at the time of freeze-thawing at two freezing rates of quick-freezing and slow-freezing against lactic acid fungal cells. 1) Preparation of wet cells Peptone (manufactured by Difco) 1%, yeast extract (manufactured by Difco) 2%, glucose (manufactured by Difco) 3%, monosodium hydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.) ) 0.5%, monosodium dihydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5%
Liquid culture medium (pH 6.5) containing Lactobacillus bulgaricus ATCC11
842 (obtained from ATCC) was inoculated and incubated at 37 ° C for 12 hours. After the completion of the culture, the bacterial cells were collected from the culture solution, washed with water, and collected again to obtain wet lactic acid bacterial cells.

【0026】2)試料の調製 この湿菌体を、各1%濃度に調整した表1に示す20種
のアミノ酸、グルタミン酸ナトリウム及びリジン塩酸塩
(いずれも和光純薬工業社製)の水溶液に、菌体固形分
濃度10%の割合で分散した試料、及び同一の湿菌体を
同様に水に分散した試料(対照)を調製した。尚、全て
の試料のpHを、10%水酸化ナトリウム溶液(ナカラ
イテスク社製)により6.5に調整した。
2) Preparation of sample This wet microbial cell was added to an aqueous solution of 20 kinds of amino acids shown in Table 1, sodium glutamate and lysine hydrochloride (all manufactured by Wako Pure Chemical Industries, Ltd.) adjusted to a concentration of 1%. A sample in which the microbial cell solid content concentration was 10% and a sample in which the same wet microbial cell was similarly dispersed in water (control) were prepared. The pH of all samples was adjusted to 6.5 with a 10% sodium hydroxide solution (Nacalai Tesque).

【0027】3)試験方法 凍結方法について 各試料を、液体窒素を用いて急速凍結し、37℃の温湯
で融解し、この凍結融解操作を5回反復した試料、及び
−30℃の冷凍庫で緩慢凍結した試料を、室温で融解
し、後記する方法により生残率を試験した。 生残率 各試料の凍結前後の生菌数を常法により測定し、次式か
ら生残率を算出した。 生残率(%)=(凍結融解後の試料1g当たりの生菌数
/凍結前の試料1g当たりの生菌数)×100
3) Test method Freezing method Each sample was rapidly frozen using liquid nitrogen, thawed in hot water at 37 ° C., and the freeze-thaw operation was repeated 5 times, and slowly in a freezer at −30 ° C. Frozen samples were thawed at room temperature and tested for viability by the method described below. Survival rate The number of viable bacteria before and after freezing of each sample was measured by a conventional method, and the survival rate was calculated from the following formula. Survival rate (%) = (the number of viable cells per 1 g of the sample after freeze-thawing / the number of viable cells per 1 g of the sample before freezing) × 100

【0028】4)試験結果 この試験結果は、表1に示すとおりである。表1から明
らかなように、アミノ酸の種類によって、生残率が大き
く異なることが認められた。特に、アスパラギン酸、ア
ルギニン、グルタミン酸、リジン、ロイシン、メチオニ
ン、プロリンの7種のアミノ酸は、急速凍結、緩慢凍結
の両条件下において、対照の水に比較して生残率の低下
が認められなかった。一方、これ以外のアミノ酸では、
急速及び緩慢凍結の双方で、対照の水より大きく生残率
が低下することが判明した。このことは、上記の7種の
アミノ酸以外のアミノ酸は、凍結条件によっては凍結に
より菌体の受ける損傷が増大していることを示してい
る。
4) Test Results The test results are shown in Table 1. As is clear from Table 1, the survival rate was significantly different depending on the type of amino acid. In particular, 7 amino acids, aspartic acid, arginine, glutamic acid, lysine, leucine, methionine, and proline, showed no decrease in survival rate compared to control water under both conditions of quick freezing and slow freezing. It was On the other hand, for other amino acids,
Both rapid and slow freezing were found to reduce viability more than control water. This indicates that amino acids other than the above-mentioned seven kinds of amino acids are more damaged by the freezing depending on freezing conditions.

【0029】また、アミノ酸誘導体であるグルタミン酸
ナトリウム及びリジン塩酸塩においてもその効果が前記
7種のアミノ酸と差異が無いこと、及びこれらと同様に
行った各アミノ酸の塩類、水和物等のアミノ酸誘導体に
ついての試験結果から、各アミノ酸の塩類、水和物等の
アミノ酸誘導体も同様の効果を有することが示された。
The effects of the amino acid derivatives sodium glutamate and lysine hydrochloride are not different from those of the above-mentioned seven kinds of amino acids, and the amino acid derivatives such as salts and hydrates of each amino acid prepared in the same manner as above. The results of the test showed that salts of each amino acid, amino acid derivatives such as hydrates, etc. also have similar effects.

【0030】以上の結果から、アスパラギン酸、アルギ
ニン、グルタミン酸、リジン、ロイシン、メチオニン、
プロリンの7種のアミノ酸又はそれらの誘導体には、こ
れ以外のアミノ酸の場合とは異なって、凍結による菌体
の損傷を軽減させる作用があり、更に、その損傷を急速
凍結、緩慢凍結の両条件においても増大させる作用が無
いことが認められた。尚、乳酸菌類の種類を変更した場
合及び凍結乾燥した場合においてもほぼ同様の結果が得
られた。
From the above results, aspartic acid, arginine, glutamic acid, lysine, leucine, methionine,
Unlike the amino acids other than these, 7 kinds of amino acids of proline or their derivatives have an action of reducing damage to cells due to freezing, and further, the damage is subjected to both quick freezing and slow freezing conditions. It was also confirmed that there was no action to increase even in. Similar results were obtained when the type of lactic acid bacteria was changed and when freeze-dried.

【0031】[0031]

【表1】 [Table 1]

【0032】試験例2 この試験は、アミノ酸混合物の乳酸菌類に対する凍結保
護効果を調べるために行った。 1)湿菌体の調製 試験例1と同一の方法により湿菌体を得た。
Test Example 2 This test was conducted to examine the cryoprotective effect of the amino acid mixture against lactic acid bacteria. 1) Preparation of wet bacterial cells Wet bacterial cells were obtained by the same method as in Test Example 1.

【0033】2)試料の調製 表2に示すとおり20種のアミノ酸から2〜8種を混合
し、アミノ酸総量として4%のアミノ酸混合水溶液(p
Hを6.5に調整)を調製し、前記湿菌体を菌体固形分
濃度10%の割合で分散した試料、10%の濃度で脱脂
粉乳を水に溶解した溶液に、同一の湿菌体を分散した試
料(対照)、及び4%のペプトン水に分散した試料(対
照)を調製した。
2) Preparation of sample As shown in Table 2, 2 to 8 kinds of amino acids were mixed from 20 kinds of amino acids, and the total amount of amino acids was 4%.
H was adjusted to 6.5), and the same wet bacterium was added to a sample in which the wet microbial cell was dispersed at a microbial cell solid concentration of 10%, and skim milk powder was dissolved in water at a concentration of 10%. A body dispersed sample (control) and a sample dispersed in 4% peptone water (control) were prepared.

【0034】3)試験方法 試験例1と同一の方法により、菌体の凍結融解を行った
試料を調製し、生残率を試験した。
3) Test method By the same method as in Test Example 1, a sample in which the cells were freeze-thawed was prepared and the survival rate was tested.

【0035】4)結果 この試験の結果は、表2に示すとおりである。表2にお
いて、Xは、アスパラギン酸、アルギニン、グルタミン
酸、リジン、ロイシン、メチオニン、プロリンの7種の
アミノ酸のいずれかを示し、Zは、前記7種のアミノ酸
を除く、13種のアミノ酸のいずれかを示し、X又はZ
と表記されたアミノ酸を含む試料は、それぞれ7種又は
13種のアミノ酸混合物試料の試験結果の最低値と最高
値を示している。
4) Results The results of this test are shown in Table 2. In Table 2, X represents any of 7 kinds of amino acids of aspartic acid, arginine, glutamic acid, lysine, leucine, methionine and proline, and Z is any of 13 kinds of amino acids excluding the above 7 kinds of amino acids. Indicates X or Z
The sample containing the amino acid indicated by indicates the minimum value and the maximum value of the test results of the 7 or 13 kinds of amino acid mixture samples, respectively.

【0036】表2から明らかなように、アスパラギン
酸、アルギニン、グルタミン酸、リジン、ロイシン、メ
チオニン、プロリンの7種のアミノ酸から選択した3種
以上のアミノ酸混合物において、緩慢凍結、急速凍結の
両条件下で菌体の生残率が高く、菌体の凍結融解による
損傷を軽減していることが判明した。これらの生残率
は、各アミノ酸単独の試料又は2種混合の試料に比較し
て明らかに高い値を示した。尚、2種類のアミノ酸混合
物として、表2記載以外の組み合わせについても試験を
行ったが、ほぼ同様の結果であった。
As is clear from Table 2, in a mixture of 3 or more kinds of amino acids selected from 7 kinds of amino acids of aspartic acid, arginine, glutamic acid, lysine, leucine, methionine and proline, both slow-freezing and quick-freezing were performed. It was found that the cell survival rate was high and damage due to freeze-thawing of the cells was reduced. These survival rates were clearly higher than those of the sample containing each amino acid alone or the sample containing a mixture of two kinds of amino acids. In addition, as a mixture of two kinds of amino acids, the test was conducted for combinations other than those shown in Table 2, but the results were almost the same.

【0037】一方、前記7種以外のアミノ酸が添加され
た場合、いずれの場合にも生残率が顕著に低下した。こ
れらのことから、前記のアミノ酸の3種以上の混合物に
は乳酸菌類の凍結に対する損傷を大きく軽減する作用が
あること、及び前記7種以外のアミノ酸の混合物は、そ
の保護効果が減少することが示された。尚、他の乳酸菌
類及び他の微生物についても試験したが、ほぼ同様の結
果が得られた。また、凍結乾燥した場合においてもほぼ
同様の結果が得られた。
On the other hand, when amino acids other than the above-mentioned 7 kinds were added, the survival rate was remarkably lowered in all cases. From these facts, a mixture of three or more kinds of the above amino acids has an action of significantly reducing damage to lactic acid bacteria against freezing, and a mixture of amino acids other than the above seven kinds of amino acids has a reduced protective effect. Was shown. Although other lactic acid bacteria and other microorganisms were also tested, almost the same results were obtained. Also, almost the same results were obtained when freeze-dried.

【0038】[0038]

【表2】 [Table 2]

【0039】試験例3 この試験は、当該アミノ酸混合物の濃度が与える凍結融
解時の菌体の生残率の影響を調べるために行った。 1)試料の調製 試験例1と同様の方法により湿菌体を調製した。
Test Example 3 This test was carried out in order to investigate the influence of the concentration of the amino acid mixture on the survival rate of the cells during freeze-thawing. 1) Preparation of sample Wet cells were prepared in the same manner as in Test Example 1.

【0040】2)試料の調製 アスパラギン酸、アルギニン、グルタミン酸、リジン、
ロイシン、メチオニン、プロリンの7種のアミノ酸か
ら、表3に示す2組の3種を選択して混合し、アミノ酸
総量として0.1、0.5、2.0、10.0、20.
0、30.0、50.0%の各アミノ酸混合水溶液(p
Hを6.5に調整)を調製し、湿菌体を菌体固形分濃度
12%の割合で分散した試料、及び同一の湿菌体を同様
に4%ペプトンに分散した試料(対照)を調製した。
2) Preparation of sample Aspartic acid, arginine, glutamic acid, lysine,
From the 7 kinds of amino acids of leucine, methionine and proline, two sets of 3 kinds shown in Table 3 are selected and mixed, and the total amount of amino acids is 0.1, 0.5, 2.0, 10.0, 20.
0, 30.0, 50.0% amino acid mixed aqueous solution (p
H was adjusted to 6.5) to prepare a sample in which wet cells were dispersed at a cell solid concentration of 12%, and a sample in which the same wet cells were similarly dispersed in 4% peptone (control). Prepared.

【0041】3)試験方法 試験例1と同一の方法により、菌体の凍結融解を行った
試料を調製し、生残率を試験した。
3) Test Method By the same method as in Test Example 1, a sample in which the cells were freeze-thawed was prepared and the survival rate was tested.

【0042】4)結果 この試験の結果は表3に示すとおりである。表3から明
らかなように、菌体分散液に対する当該アミノ酸混合物
の濃度が、0.5%未満の試料は、乳酸菌類の凍結融解
に対する生残率の増加が認められず、濃度が30%を超
える試料は、添加割合の増加にともなう生残率の増加が
認められなかった。これに対して、菌体分散液に対する
当該アミノ酸混合物の濃度が0.5〜30%の範囲の試
料では、生残率の増加が認められ、特に2〜20%の範
囲において高い生残率が認められた。従って、菌体分散
液に対する当該アミノ酸混合物の添加割合は、アミノ酸
総量として0.5〜30%、望ましくは2〜20%であ
る。尚、乳酸菌類及びアミノ酸の種類を変更して試験し
たが、ほぼ同様の結果が得られた。また、凍結乾燥した
場合においてもほぼ同様の結果が得られた。
4) Results The results of this test are shown in Table 3. As is clear from Table 3, in the sample in which the concentration of the amino acid mixture in the bacterial cell dispersion liquid is less than 0.5%, no increase in the survival rate due to freeze-thawing of lactic acid bacteria was observed, and the concentration was 30%. In the samples exceeding the above range, the survival rate did not increase with the increase of the addition ratio. On the other hand, in the sample in which the concentration of the amino acid mixture in the bacterial cell dispersion liquid is in the range of 0.5 to 30%, the survival rate is increased, and particularly in the range of 2 to 20%, the high survival rate is observed. Admitted. Therefore, the ratio of the amino acid mixture to be added to the bacterial cell dispersion liquid is 0.5 to 30%, preferably 2 to 20% as the total amount of amino acids. In addition, the lactic acid bacteria and the types of amino acids were changed and tested, but almost the same results were obtained. Also, almost the same results were obtained when freeze-dried.

【0043】[0043]

【表3】 [Table 3]

【0044】試験例4 この試験は、各種乳酸菌類の凍結融解に対する当該アミ
ノ酸混合物の効果を調べるために行った。 1)湿菌体の調製 2%の割合でグルコ−ス(ディフコ社製)を添加したG
AM液体培地(ニッスイ社製)に、ストレプトコッカス
・サ−モフィルス(Streptococcus thermophilus)AT
CC19258株(ATCCから入手)、ラクトバシラ
ス・アシドフィルス(Lactobacillus acidophilus)AT
CC4356株(ATCCから入手)、エンテロコッカ
ス・フェカーリス(Enterococcus faecalis)ATCC1
9433株(ATCCから入手)、ビフィドバクテリウ
ム・ロングム(Bifidobacteriumlongum)ATCC15
707株(ATCCから入手)をそれぞれ別個に接種
し、37℃で12時間培養した。培養終了後、培養液か
ら菌体を集菌し、水で洗浄し、再び集菌し、各乳酸菌類
の湿菌体を得た。
Test Example 4 This test was conducted to examine the effect of the amino acid mixture on freeze-thawing of various lactic acid bacteria. 1) Preparation of wet bacterial cells G to which glucose (manufactured by Difco) was added at a rate of 2%
Streptococcus thermophilus AT in AM liquid medium (manufactured by Nissui)
CC19258 strain (obtained from ATCC), Lactobacillus acidophilus AT
CC4356 strain (obtained from ATCC), Enterococcus faecalis ATCC1
9433 strain (obtained from ATCC), Bifidobacterium longum ATCC15
Strain 707 (obtained from ATCC) was separately inoculated and cultured at 37 ° C. for 12 hours. After the completion of the culture, the bacterial cells were collected from the culture solution, washed with water, and collected again to obtain wet bacterial cells of each lactic acid bacterium.

【0045】2)試料の調製 湿菌体をL(+)アスパラギン酸ナトリウム一水和物
(和光純薬工業社製)、一塩酸Lリジン(和光純薬工業
社製)、L(+)アルギニン塩酸塩(和光純薬工業社
製)、Lプロリン(和光純薬工業社製)を各4%の濃度
で含有する水溶液に、菌体固形分濃度10%の割合で分
散し、pHを6.5に調整した試料(試料1)、脱脂粉
乳及びグルタミン酸ナトリウムを各8%の濃度で水に溶
解した溶液に、同一の湿菌体を分散し、pHを6.5に
調整した試料(対照)を調製し、以下試験例1と同一の
方法により緩慢凍結及び急速凍結した。
2) Preparation of samples Wet cells were L (+) sodium aspartate monohydrate (Wako Pure Chemical Industries, Ltd.), L-lysine monohydrochloride (Wako Pure Chemical Industries, Ltd.), L (+) arginine. Disperse the aqueous solution containing 4% of each of hydrochloride (Wako Pure Chemical Industries, Ltd.) and L proline (Wako Pure Chemical Industries, Ltd.) at a concentration of 10% of the solid content of the cells to adjust the pH to 6. Sample (sample 1) adjusted to 5; skim milk powder and sodium glutamate dissolved in water at a concentration of 8% each, the same wet bacterial cells were dispersed, and the pH was adjusted to 6.5 (control) Was prepared and then slowly frozen and rapidly frozen in the same manner as in Test Example 1.

【0046】3)試験方法 試験例1と同一の方法によった。3) Test method The same method as in Test Example 1 was used.

【0047】4)試験結果 この試験結果は、表4に示すとおりである。表4から明
らかなように、いずれの菌株においても、本発明の微生
物保護剤を使用した試料1は、緩慢凍結及び急速凍結の
両条件下で、公知の保護剤のみを使用した対照よりも高
い生残性が認められた。これらの結果から、本発明の微
生物保護剤は、各種乳酸菌類の凍結融解に極めて有効で
あることが立証された。尚、乳酸菌類及びアミノ酸混合
物の種類を変更して試験したが、ほぼ同様の結果が得ら
れた。
4) Test Results The test results are shown in Table 4. As is clear from Table 4, in all of the strains, the sample 1 using the microbial protective agent of the present invention is higher than the control using only the known protective agent under both slow freezing and quick freezing conditions. Survival was observed. From these results, it was proved that the microbial protective agent of the present invention is extremely effective for freeze-thawing various lactic acid bacteria. It should be noted that, although the types of lactic acid bacteria and the amino acid mixture were changed and tested, almost the same results were obtained.

【0048】[0048]

【表4】 [Table 4]

【0049】試験例5 この試験は、各種乳酸菌類の凍結乾燥に対するアミノ酸
混合物の効果を調べるために行った。 1)湿菌体の調製 試験例4と同一の方法によった。
Test Example 5 This test was conducted to examine the effect of the amino acid mixture on the freeze-drying of various lactic acid bacteria. 1) Preparation of wet cells The same method as in Test Example 4 was used.

【0050】2)試料の調製 Lグルタミン酸一ナトリウム(和光純薬工業社製)、一
塩酸Lリジン(和光純薬工業社製)、Lプロリン(和光
純薬工業社製)、DLメチオニン(和光純薬工業社製)
を各3%の濃度で含有する水溶液に、菌体固形分濃度1
0%の割合で前記湿菌体を分散し、pHを6.5に調整
した試料(試料2)、同一の湿菌体を、脱脂粉乳及びグ
ルタミン酸ナトリウムを各8%の濃度で水に溶解した溶
液に、同一の湿菌体を分散し、pHを6.5に調整した
試料(対照)を調製した。
2) Preparation of sample L monosodium glutamate (manufactured by Wako Pure Chemical Industries, Ltd.), L lysine monohydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.), L proline (manufactured by Wako Pure Chemical Industries, Ltd.), DL methionine (Wako Pure Chemical Industries, Ltd.) (Made by Yaku Kogyo)
To an aqueous solution containing 3% of each, and a solid concentration of 1
A sample (Sample 2) in which the wet bacterial cells were dispersed at a ratio of 0% and the pH was adjusted to 6.5, and the same wet bacterial cells were dissolved in skim milk powder and sodium glutamate at a concentration of 8% each in water. The same wet bacterial cells were dispersed in the solution, and a sample (control) in which the pH was adjusted to 6.5 was prepared.

【0051】3)試験方法 各試料1mlを3mlのバイヤル瓶に入れ、−30℃の
冷凍庫で凍結させ、のち100〜200hPaの真空度
において、30℃の温度で各試料を凍結乾燥した。凍結
乾燥した各試料の菌数を常法により測定し、当該アミノ
酸混合物の凍結乾燥に対する保護効果を試験した。
3) Test Method 1 ml of each sample was placed in a 3 ml vial bottle, frozen in a freezer at -30 ° C, and then freeze-dried at a temperature of 30 ° C in a vacuum degree of 100 to 200 hPa. The number of bacteria in each freeze-dried sample was measured by a conventional method, and the protective effect of the amino acid mixture on freeze-drying was tested.

【0052】4)試験結果 この試験の結果は、表5に示すとおりである。表5から
明らかなように、当該アミノ酸混合物が、いずれの乳酸
菌類に対しても顕著に高い生残率を示し、乳酸菌類の凍
結乾燥保護効果を有することが認められた。尚、他の当
該アミノ酸混合物及び他の乳酸菌類についても試験した
が、ほぼ同様の結果が得られた。
4) Test Results The results of this test are shown in Table 5. As is clear from Table 5, it was confirmed that the amino acid mixture had a remarkably high survival rate against any lactic acid bacteria and had a freeze-drying protective effect on the lactic acid bacteria. The other amino acid mixtures and other lactic acid bacteria were also tested, but almost the same results were obtained.

【0053】[0053]

【表5】 [Table 5]

【0054】[0054]

【実施例】次に、実施例を示して本発明を更に詳述する
が、本発明は、以下の実施例に限定されるものではな
い。 実施例1 L(+)アスパラギン酸ナトリウム一水和物(和光純薬
工業社製)100g、Lグルタミン酸一ナトリウム(和
光純薬工業社製)100g及び一塩酸Lリジン(和光純
薬工業社製)100gを均一に混合し、合成樹脂製の袋
(大日本印刷社製)に充填し、密封し、微生物保護剤約
300gを得た。
EXAMPLES Next, the present invention will be described in more detail by showing examples, but the present invention is not limited to the following examples. Example 1 100 g of L (+) sodium aspartate monohydrate (manufactured by Wako Pure Chemical Industries, Ltd.), 100 g of L sodium glutamate (manufactured by Wako Pure Chemical Industries, Ltd.) and L lysine monohydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.) 100 g of the mixture was uniformly mixed, filled in a synthetic resin bag (manufactured by Dainippon Printing Co., Ltd.) and sealed to obtain about 300 g of a microbial protection agent.

【0055】実施例2 L(+)アルギニン塩酸塩(和光純薬工業社製)100
g、Lロイシン(和光純薬工業社製)100g、一塩酸
Lリジン(和光純薬工業社製)100g、Lプロリン
(和光純薬工業社製)100g及びDLメチオニン(和
光純薬工業社製)を均一に混合し、合成樹脂製の袋(大
日本印刷社製)に充填し、密封し、微生物保護剤約40
0gを得た。
Example 2 L (+) arginine hydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.) 100
g, L leucine (Wako Pure Chemical Industries, Ltd.) 100 g, L lysine monohydrochloride (Wako Pure Chemical Industries, Ltd.) 100 g, L proline (Wako Pure Chemical Industries, Ltd.) 100 g, and DL methionine (Wako Pure Chemical Industries, Ltd.) Are evenly mixed, filled in a bag made of synthetic resin (manufactured by Dai Nippon Printing Co., Ltd.) and sealed, and a microbial protection agent of about 40
0 g was obtained.

【0056】実施例3 Lグルタミン酸一ナトリウム(和光純薬工業社製)50
g、一塩酸Lリジン(和光純薬工業社製)50g、L
(+)アルギニン塩酸塩(和光純薬工業社製)50g及
びLロイシン(和光純薬工業社製)50gを均一に混合
し、合成樹脂製の袋(大日本印刷社製)に充填し、密封
し、微生物保護剤約200gを得た。
Example 3 Monosodium L-glutamate (manufactured by Wako Pure Chemical Industries, Ltd.) 50
g, L-lysine monohydrochloride (Wako Pure Chemical Industries, Ltd.) 50 g, L
(+) Arginine hydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.) 50 g and L-leucine (manufactured by Wako Pure Chemical Industries, Ltd.) 50 g are uniformly mixed and filled in a synthetic resin bag (manufactured by Dai Nippon Printing Co., Ltd.) and sealed. Then, about 200 g of a microbial protection agent was obtained.

【0057】実施例4 Lグルタミン酸一ナトリウム(和光純薬工業社製)40
g、一塩酸Lリジン(和光純薬工業社製)40g、L
(+)アルギニン塩酸塩(和光純薬工業社製)40g、
Lプロリン(和光純薬工業社製)40g及びDLメチオ
ニン(和光純薬工業社製)40gを均一に混合し、合成
樹脂製の袋(大日本印刷社製)に充填し、密封し、微生
物保護剤約200gを得た。
Example 4 Monosodium L-glutamate (Wako Pure Chemical Industries, Ltd.) 40
40 g of L lysine monohydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.), L
(+) Arginine hydrochloride (Wako Pure Chemical Industries, Ltd.) 40 g,
L-proline (Wako Pure Chemical Industries, Ltd.) 40 g and DL methionine (Wako Pure Chemical Industries, Ltd.) 40 g were uniformly mixed, filled in a synthetic resin bag (Dainippon Printing Co., Ltd.), sealed, and protected with microorganisms. About 200 g of the agent was obtained.

【0058】実施例5 L(+)アスパラギン酸ナトリウム一水和物(和光純薬
工業社製)80g、一塩酸Lリジン(和光純薬工業社
製)80g、L(+)アルギニン塩酸塩(和光純薬工業
社製)80g、Lプロリン(和光純薬工業社製)80g
及びDLメチオニン(和光純薬工業社製)80gを均一
に混合し、合成樹脂製の袋(大日本印刷社製)に充填
し、密封し、微生物保護剤約400gを得た。
Example 5 80 g of L (+) sodium aspartate monohydrate (manufactured by Wako Pure Chemical Industries, Ltd.), 80 g of L-lysine monohydrochloride (manufactured by Wako Pure Chemical Industries, Ltd.), L (+) arginine hydrochloride (sum Kogaku Yakuhin Kogyo Co., Ltd.) 80 g, L proline (Wako Junyaku Kogyo KK) 80 g
Further, 80 g of DL methionine (manufactured by Wako Pure Chemical Industries, Ltd.) was uniformly mixed, filled in a bag made of synthetic resin (manufactured by Dai Nippon Printing Co., Ltd.) and sealed to obtain about 400 g of a microbial protectant.

【0059】実施例6 L(+)アスパラギン酸ナトリウム一水和物(和光純薬
工業社製)20g、Lグルタミン酸一ナトリウム(和光
純薬工業社製)20g、L(+)アルギニン塩酸塩(和
光純薬工業社製)20g、Lプロリン(和光純薬工業社
製)20g及びDLメチオニン(和光純薬工業社製)2
0gを均一に混合し、合成樹脂製の袋(大日本印刷社
製)に充填し、密封し、微生物保護剤約100gを得
た。
Example 6 20 g of sodium L (+) aspartate monohydrate (manufactured by Wako Pure Chemical Industries, Ltd.), 20 g of monosodium L glutamate (manufactured by Wako Pure Chemical Industries, Ltd.), L (+) arginine hydrochloride (sum Kogaku Yakuhin Co., Ltd.) 20 g, L-proline (Wako Pure Chemical Industries, Ltd.) 20 g and DL methionine (Wako Pure Chemical Industries, Ltd.) 2
0 g was uniformly mixed, filled in a synthetic resin bag (manufactured by Dainippon Printing Co., Ltd.), and sealed to obtain about 100 g of a microbial protection agent.

【0060】実施例7 L(+)アスパラギン酸ナトリウム一水和物(和光純薬
工業社製)30g、Lグルタミン酸一ナトリウム(和光
純薬工業社製)30g、一塩酸Lリジン(和光純薬工業
社製)30g、L(+)アルギニン塩酸塩(和光純薬工
業社製)30g、Lプロリン(和光純薬工業社製)30
g及びDLメチオニン(和光純薬工業社製)30gを均
一に混合し、合成樹脂製の袋(大日本印刷社製)に充填
し、密封し、微生物保護剤約180gを得た。
Example 7 30 g of L (+) sodium aspartate monohydrate (manufactured by Wako Pure Chemical Industries, Ltd.), 30 g of monosodium L glutamate (manufactured by Wako Pure Chemical Industries, Ltd.), L lysine monohydrochloride (Wako Pure Chemical Industries, Ltd.) 30 g, L (+) arginine hydrochloride (Wako Pure Chemical Industries, Ltd.) 30 g, L proline (Wako Pure Chemical Industries, Ltd.) 30
g and DL methionine (manufactured by Wako Pure Chemical Industries, Ltd.) were uniformly mixed, filled in a bag made of synthetic resin (manufactured by Dai Nippon Printing Co., Ltd.) and sealed to obtain about 180 g of a microbial protectant.

【0061】実施例8 L(+)アスパラギン酸ナトリウム一水和物(和光純薬
工業社製)20g、Lグルタミン酸一ナトリウム(和光
純薬工業社製)20g、一塩酸Lリジン(和光純薬工業
社製)20g、L(+)アルギニン塩酸塩(和光純薬工
業社製)20g、Lプロリン(和光純薬工業社製)20
g、Lロイシン(和光純薬工業社製)20g及びDLメ
チオニン(和光純薬工業社製)20gを均一に混合し、
合成樹脂製の袋(大日本印刷社製)に充填し、密封し、
微生物保護剤約140gを得た。
Example 8 20 g of L (+) sodium aspartate monohydrate (manufactured by Wako Pure Chemical Industries, Ltd.), 20 g of monosodium L glutamate (manufactured by Wako Pure Chemical Industries, Ltd.), L lysine monohydrochloride (Wako Pure Chemical Industries, Ltd.) 20 g, L (+) arginine hydrochloride (Wako Pure Chemical Industries, Ltd.) 20 g, L proline (Wako Pure Chemical Industries, Ltd.) 20
g, L leucine (manufactured by Wako Pure Chemical Industries, Ltd.) 20 g and DL methionine (manufactured by Wako Pure Chemical Industries, Ltd.) 20 g are uniformly mixed,
Fill a synthetic resin bag (manufactured by Dai Nippon Printing Co., Ltd.) and seal it.
About 140 g of a microbial protection agent was obtained.

【0062】実施例9 ペプトン(ディフコ社製)1%、酵母エキス(ディフコ
社製)2%、グルコ−ス(ディフコ社製)3%、リン酸
1水素2ナトリウム(和光純薬工業社製)0.5%、リ
ン酸2水素1ナトリウム(和光純薬工業社製)0.5%
を含む液体培地(pH6.5)300mlにラクトバシ
ラス・ブルガリカス(Lactobacillus bulgaricus)AT
CC11842(ATCCから入手)を接種し、37℃
で12時間培養し、2.5×108 CFU/mlの乳酸
菌液300mlを得た。この菌液を、冷蔵庫で冷却し、
300mlの遠心管に入れ、遠心機(トミ−精工社製)
により6,000×gで20分間遠心分離を行い、デカ
ンテ−ションにより上澄液を除去し、沈殿した湿菌体に
300mlの滅菌水(4℃)を添加し、湿菌体を分散
し、再び同一条件で遠心分離を行い、上澄液を同様に除
去し、湿菌体約0.5gを得た。
Example 9 Peptone (manufactured by Difco) 1%, yeast extract (manufactured by Difco) 2%, glucose (manufactured by Difco) 3%, disodium monohydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.5%, sodium dihydrogen phosphate 0.5% (manufactured by Wako Pure Chemical Industries, Ltd.)
Lactobacillus bulgaricus AT in 300 ml of liquid medium (pH 6.5) containing
CC11842 (obtained from ATCC), 37 ° C
After culturing for 12 hours, 300 ml of 2.5 × 10 8 CFU / ml lactic acid bacterium solution was obtained. Cool this bacterial solution in the refrigerator,
Put in a 300 ml centrifuge tube, centrifuge (Tomi-Seiko Co., Ltd.)
By centrifugation at 6,000 xg for 20 minutes, the supernatant is removed by decantation, and 300 ml of sterilized water (4 ° C) is added to the precipitated wet cells to disperse the wet cells. Centrifugation was performed again under the same conditions, and the supernatant was similarly removed to obtain about 0.5 g of wet bacterial cells.

【0063】この湿菌体に実施例1の微生物保護剤3.
6gを水に溶解した溶液30mlを添加し、菌体を分散
させ、のち10%水酸化ナトリウム(ナカライテスク社
製)溶液でpHを6.5に調整し、菌体分散液を調製し
た。この分散液を3mlずつ10mlのバイアル瓶(日
電理化学社製)に充填し、内3本を液体窒素に2分間浸
し、急速凍結を行い、乳酸菌急速凍結菌体を得た。ま
た、別のバイアル瓶3本を−30℃の冷凍庫(サンヨ−
社製)中に1時間放置し、緩慢凍結を行い、乳酸菌緩慢
凍結菌体を得た。
The wet bacterial cells were treated with the microbial protective agent of Example 1.
30 ml of a solution prepared by dissolving 6 g in water was added to disperse the cells, and the pH was adjusted to 6.5 with a 10% sodium hydroxide (Nacalai Tesque, Inc.) solution to prepare a cell dispersion. 3 ml of this dispersion was filled in a 10 ml vial bottle (manufactured by Nichiden Rikagaku Co., Ltd.), three of which were immersed in liquid nitrogen for 2 minutes and rapidly frozen to obtain lactic acid bacteria rapidly frozen cells. Also, put three other vials in a freezer (Sanyo-
The product was left for 1 hour in S.A. and slowly frozen to obtain lactic acid bacteria slowly frozen cells.

【0064】得られた各凍結菌体を室温で30分間放置
して融解し、試験例1と同一の方法により生残率を測定
した結果、急速凍結したバイアル瓶では92.2%,緩
慢凍結したバイアル瓶では94.1%であり、いずれも
高い生残率を維持していた。
The frozen cells thus obtained were left to thaw at room temperature for 30 minutes to be thawed, and the survival rate was measured by the same method as in Test Example 1. As a result, in the rapidly frozen vial, it was 92.2%, slowly frozen. It was 94.1% in the vials, and all of them maintained a high survival rate.

【0065】実施例10 実施例1と同一の方法で得た乳酸菌の湿菌体0.5g
に、実施例2の微生物保護剤2.4gを水に溶解した溶
液20mlを添加し、湿菌体を分散し、10%水酸化ナ
トリウム(ナカライテスク社製)溶液によりpH6.5
に調整し、菌体分散液を調製した。この分散液をトレ−
に流し込み、凍結乾燥機(エドワ−ズ社製)を用いて−
40℃に冷却して凍結し、のち30℃、真空度10Pa
の条件下で凍結乾燥し、約1.5gの凍結乾燥菌体を得
た。
Example 10 0.5 g of wet lactic acid bacteria obtained by the same method as in Example 1
To this, 20 ml of a solution prepared by dissolving 2.4 g of the microorganism protecting agent of Example 2 in water was added to disperse the wet cells, and the pH was adjusted to 6.5 with a 10% sodium hydroxide (Nacalai Tesque, Inc.) solution.
To prepare a bacterial cell dispersion liquid. Trace this dispersion
Pour into a lyophilizer and use a freeze dryer (Edwards Co., Ltd.)-
Cool to 40 ℃ and freeze, then 30 ℃, vacuum 10Pa
Freeze-drying was performed under the conditions described above to obtain about 1.5 g of freeze-dried cells.

【0066】得られた凍結乾燥菌体を、次式に従って生
残率を測定した結果、33.4%であり、高い生残率を
維持していた。 生残率(%)=[凍結乾燥後1g当たりの生菌数×凍結
乾燥前溶液固形分(%)/凍結前1g当たりの生菌数×
100]×100
The survival rate of the freeze-dried microbial cells thus obtained was measured according to the following formula, and as a result, it was 33.4%, and the high survival rate was maintained. Survival rate (%) = [Number of viable bacteria per 1 g after freeze-drying x Solid content of solution before freeze-drying (%) / Number of viable bacteria per 1 g before freeze-drying x)
100] x 100

【0067】実施例11 ペプトン(ディフコ社製)1%、酵母エキス(ディフコ
社製)2%、グルコ−ス(ディフコ社製)2%、リン酸
1水素2ナトリウム(和光純薬工業社製)0.2%、リ
ン酸2水素1ナトリウム(和光純薬工業社製)0.4%
を含む液体培地(pH6.5)300mlにビフィドバ
クテリウム・ロングム(Bifidobacteriumlongum)AT
CC15707株(ATCCより入手)を接種し、37
℃で16時間培養し、1.5×109 CFU/mlのビ
フィズス菌液300mlを得た。この菌液を、冷蔵庫で
冷却し、300mlの遠心管に入れ、遠心機(トミ−精
工社製)により6,000×gで20分間の遠心分離を
行い、デカンテ−ションにより上澄液を除去し、沈殿し
た湿菌体に300mlの滅菌水(4℃)を添加し、湿菌
体を分散し、再び同一の条件で遠心分離を行い、上澄液
を同様に除去し、湿菌体約0.5gを得た。
Example 11 Peptone (manufactured by Difco) 1%, yeast extract (manufactured by Difco) 2%, glucose (manufactured by Difco) 2%, disodium monohydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.2%, monosodium dihydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.4%
Bifidobacterium longum AT in 300 ml of liquid medium (pH 6.5) containing
CC15707 strain (obtained from ATCC) was inoculated and 37
After culturing for 16 hours at .degree. C., 300 ml of a 1.5.times.10@9 CFU / ml bifidobacteria solution was obtained. This bacterial solution was cooled in a refrigerator, placed in a 300 ml centrifuge tube, centrifuged at 6,000 xg for 20 minutes by a centrifuge (Tomi Seiko Co., Ltd.), and the supernatant was removed by decantation. Then, 300 ml of sterilized water (4 ° C.) was added to the precipitated wet cells to disperse the wet cells, centrifuge again under the same conditions, and the supernatant was removed in the same manner. 0.5 g was obtained.

【0068】この湿菌体に、実施例3の微生物保護剤
2.4gを水に溶解した溶液30mlを添加し、菌体を
分散させ、のち10%水酸化ナトリウム(ナカライテス
ク社製)溶液でpHを6.5に調整し、菌体分散液を調
製した。この分散液を3mlずつ10mlのバイアル瓶
(日電理化学社製)に充填し、内3本を液体窒素に2分
間浸し、急速凍結を行い、ビフィズス菌急速凍結菌体を
得た。また、別の3本を−30℃の冷凍庫(サンヨ−社
製)中に1時間放置し、緩慢凍結を行い、ビフィズス菌
緩慢凍結菌体を得た。
To the wet cells, 30 ml of a solution prepared by dissolving 2.4 g of the microorganism-protecting agent of Example 3 in water was added to disperse the cells, and then 10% sodium hydroxide (Nacalai Tesque) solution was used. The pH was adjusted to 6.5 to prepare a bacterial cell dispersion liquid. 3 ml of this dispersion was filled in a 10 ml vial bottle (manufactured by Nichiden Rikagaku Co., Ltd.), three of which were immersed in liquid nitrogen for 2 minutes and rapidly frozen to obtain bifidobacterium rapidly frozen cells. Further, the other three were left in a freezer (manufactured by Sanyo Co., Ltd.) at -30 ° C. for 1 hour and slowly frozen to obtain bifidobacterium slowly frozen cells.

【0069】得られた各凍結菌体を室温で30分間放置
して融解し、試験例1と同一の方法により生残率を測定
した結果、急速凍結したバイアル瓶では95.5%,緩
慢凍結したバイアル瓶では93.1%であり、いずれも
高い生残率を維持していた。
The frozen cells thus obtained were allowed to thaw at room temperature for 30 minutes to thaw them, and the survival rate was measured by the same method as in Test Example 1. As a result, in a rapidly frozen vial, it was 95.5%, slowly frozen. It was 93.1% in all the vials, and the high survival rate was maintained in each case.

【0070】実施例12 ペプトン(ディフコ社製)1%、酵母エキス(ディフコ
社製)1%、グルコ−ス(ディフコ社製)1%、リン酸
1水素2ナトリウム(和光純薬工業社製)0.2%、リ
ン酸2水素1ナトリウム(和光純薬工業社製)0.2%
を含む液体培地(pH6.5)300mlにバシラス・
サチリス(Bacillus subtilis)ATCC6633株(A
TCCより入手)を接種し、30℃で12時間培養し、
2.2×108 CFU/mlの菌液300mlを得た。
この菌液を、冷蔵庫で冷却し、300mlの遠心管に入
れ、遠心機(トミ−精工社製)により5,000×gで
15分間の遠心分離を行い、デカンテ−ションにより上
澄液を除去し、沈殿した湿菌体に300mlの滅菌水
(4℃)を添加し、湿菌体を分散し、再び同一の条件で
遠心分離を行い、上澄液を同様に除去し、湿菌体約0.
4gを得た。
Example 12 Peptone (manufactured by Difco) 1%, yeast extract (manufactured by Difco) 1%, glucose (manufactured by Difco) 1%, disodium monohydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.) 0.2%, dihydrogen phosphate monosodium (Wako Pure Chemical Industries, Ltd.) 0.2%
To 300 ml of liquid medium (pH 6.5) containing
Bacillus subtilis ATCC6633 strain (A
(Obtained from TCC), incubate at 30 ° C for 12 hours,
300 ml of a bacterial solution of 2.2 × 10 8 CFU / ml was obtained.
This bacterial solution was cooled in a refrigerator, placed in a 300 ml centrifuge tube, centrifuged at 5,000 xg for 15 minutes by a centrifuge (Tomi Seiko Co., Ltd.), and the supernatant was removed by decantation. Then, 300 ml of sterilized water (4 ° C.) was added to the precipitated wet cells to disperse the wet cells, centrifuge again under the same conditions, and the supernatant was removed in the same manner. 0.
4 g was obtained.

【0071】この湿菌体に、実施例4の微生物保護剤
1.8gを水に溶解した溶液30mlを添加し、菌体を
分散させ、のち10%水酸化ナトリウム(ナカライテス
ク社製)溶液でpHを6.5に調整し、菌体分散液を調
製した。この分散液を3mlずつ10mlのバイアル瓶
(日電理化学社製)に充填し、内3本を液体窒素に2分
間浸し、急速凍結を行い、バシラス・サブチルス菌急速
凍結菌体を得た。また、別の3本を−30℃の冷凍庫
(サンヨ−社製)中に1時間放置し、緩慢凍結を行い、
バシラス・サブチルス菌緩慢凍結菌体を得た。
To the wet cells, 30 ml of a solution prepared by dissolving 1.8 g of the microorganism-protecting agent of Example 4 in water was added to disperse the cells, and then 10% sodium hydroxide (Nacalai Tesque) solution was used. The pH was adjusted to 6.5 to prepare a bacterial cell dispersion liquid. 3 ml of this dispersion was filled into a 10 ml vial bottle (manufactured by Nichiden Rikagaku Co., Ltd.), three of which were immersed in liquid nitrogen for 2 minutes, and quick frozen to obtain Bacillus subtilis rapidly frozen bacterial cells. Also, the other three were left in a freezer (manufactured by Sanyo Co., Ltd.) at -30 ° C for 1 hour to slowly freeze them,
Slowly frozen cells of Bacillus subtilis were obtained.

【0072】得られた各凍結菌体を室温で30分間放置
して融解し、試験例1と同一の方法により生残率を測定
した結果、急速凍結したバイアル瓶では97.7%,緩
慢凍結したバイアル瓶では95.7%であり、いずれも
高い生残率を維持していた。
The frozen cells thus obtained were allowed to thaw for 30 minutes at room temperature and thawed, and the survival rate was measured by the same method as in Test Example 1. As a result, 97.7% was slowly frozen in the rapidly frozen vial bottle. It was 95.7% in the vials, and all of them maintained a high survival rate.

【0073】実施例13 ペプトン(ディフコ社製)0.3%、酵母エキス(ディ
フコ社製)0.4%、グルコ−ス(ディフコ社製)3
%、リン酸1水素2ナトリウム(和光純薬工業社製)
0.2%、リン酸2水素1ナトリウム(和光純薬工業社
製)0.2%を含む液体培地(pH6.5)300ml
にサッカロミセス・カ−ルスバ−ジェンシス(Sacckaro
myces carlsbergensis)ATCC9080株(ATCC
より入手)を接種し、25℃で20時間培養し、1.2
×107 CFU/mlの菌液300mlを得た。この菌
液を、冷蔵庫で冷却し、300mlの遠心管に入れ、遠
心機(トミ−精工社製)により7,000×gで10分
間の遠心分離を行い、デカンテ−ションにより上澄液を
除去し、沈殿した湿菌体に300mlの滅菌水(4℃)
を添加し、湿菌体を分散し、再び同一の条件で遠心分離
を行い、上澄液を同様に除去し、湿菌体約0.4gを得
た。
Example 13 Peptone (manufactured by Difco) 0.3%, yeast extract (manufactured by Difco) 0.4%, glucose (manufactured by Difco) 3
%, Disodium hydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.)
300 ml of liquid medium (pH 6.5) containing 0.2% and 0.2% of sodium dihydrogen phosphate (manufactured by Wako Pure Chemical Industries, Ltd.)
Saccharomyces calsvar Jensis (Sacckaro
myces carlsbergensis) ATCC9080 strain (ATCC
1.2) and incubate at 25 ° C for 20 hours.
300 ml of a bacterial solution of × 10 7 CFU / ml was obtained. This bacterial solution was cooled in a refrigerator, placed in a 300 ml centrifuge tube, and centrifuged at 7,000 xg for 10 minutes by a centrifuge (Tomi Seiko Co., Ltd.), and the supernatant was removed by decantation. Then, 300 ml of sterilized water (4 ° C) was added to the precipitated wet cells.
Was added to disperse the wet microbial cells, centrifugation was again performed under the same conditions, and the supernatant was similarly removed to obtain about 0.4 g of wet microbial cells.

【0074】この湿菌体に、実施例5の微生物保護剤
2.8gを水に溶解した溶液30mlを添加し、菌体を
分散させ、のち10%水酸化ナトリウム(ナカライテス
ク社製)溶液でpHを6.5に調整し、菌体分散液を調
製した。この分散液を3mlずつ10mlのバイアル瓶
(日電理化学社製)に充填し、内3本を液体窒素に2分
間浸し、急速凍結を行い、酵母急速凍結菌体を得た。ま
た、別の3本を−30℃の冷凍庫(サンヨ−電気社製)
中に1時間放置し、緩慢凍結を行い、酵母緩慢凍結菌体
を得た。
To the wet cells, 30 ml of a solution prepared by dissolving 2.8 g of the microorganism-protecting agent of Example 5 in water was added to disperse the cells, and then 10% sodium hydroxide (Nacalai Tesque) solution was used. The pH was adjusted to 6.5 to prepare a bacterial cell dispersion liquid. 3 ml of this dispersion was filled into a 10 ml vial bottle (manufactured by Nichiden Rikagaku Co., Ltd.), three of which were immersed in liquid nitrogen for 2 minutes, and quick freeze was performed to obtain yeast freeze-frozen cells. In addition, another three are stored in a freezer at -30 ° C (manufactured by Sanyo Electric Co., Ltd.)
It was left inside for 1 hour and slowly frozen to obtain yeast slowly frozen cells.

【0075】得られた各凍結菌体を室温で30分間放置
して融解し、試験例1と同一の方法により生残率を測定
した結果、急速凍結したバイアル瓶では94.1%,緩
慢凍結したバイアル瓶では93.2%であり、いずれも
高い生残率を維持していた。
The frozen cells thus obtained were left to thaw at room temperature for 30 minutes to be thawed, and the survival rate was measured by the same method as in Test Example 1. As a result, in the rapidly frozen vial bottle, 94.1%, slowly frozen. It was 93.2% in all the vials, and the high survival rate was maintained in each case.

【0076】[0076]

【発明の効果】以上詳記したとおり、本発明は、特定の
アミノ酸の混合物又はそれらの誘導体の混合物を含有し
てなる凍結時又は凍結乾燥時の微生物保護剤、及び当該
微生物保護剤を使用し、高い生残率を有する凍結又は凍
結乾燥微生物菌体を製造する方法に係るものであり、本
発明によって奏せられる効果は、次のとおりである。 1)凍結又は凍結乾燥工程において損傷又は死滅が少な
く、かつ高い生残率を有する微生物の凍結菌体又は凍結
乾燥菌体が得られる。 2)急速凍結、緩慢凍結等の凍結速度に無関係に、高い
生残率を有する微生物の凍結菌体又は凍結乾燥菌体が得
られる。 3)当該微生物保護剤が特定のアミノ酸の混合物又はそ
れらの誘導体の混合物から構成されるものであるため、
保護剤溶解時の作業性が良好であり、かつ安定性が高
く、更に、その溶解水は無色透明であるため菌体分散後
の菌の状態を容易に観察することができる。 4)当該微生物保護剤の溶液は、緩衝作用を有するの
で、分散させた微生物によるpHの変動を抑制し得る。
INDUSTRIAL APPLICABILITY As described in detail above, the present invention uses a microbial protecting agent containing a mixture of specific amino acids or a derivative thereof during freezing or lyophilization, and the microbial protecting agent. The present invention relates to a method for producing a frozen or freeze-dried microbial cell having a high survival rate, and the effects of the present invention are as follows. 1) Frozen cells or freeze-dried cells of microorganisms which are less damaged or killed in the freezing or freeze-drying process and have a high survival rate can be obtained. 2) Frozen cells or freeze-dried cells of microorganisms having a high survival rate can be obtained regardless of the freezing rate such as quick freezing and slow freezing. 3) Since the microbial protective agent is composed of a mixture of specific amino acids or a mixture of derivatives thereof,
The workability at the time of dissolving the protective agent is good, the stability is high, and the dissolved water is colorless and transparent, so that the state of the bacteria after dispersion of the bacterial cells can be easily observed. 4) Since the solution of the microorganism protecting agent has a buffering action, it is possible to suppress the fluctuation of pH due to the dispersed microorganisms.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI (C12N 1/20 C12R 1:01) (72)発明者 宮浦 小百合 神奈川県座間市東原5丁目1番83号 森 永乳業株式会社栄養科学研究所内 (56)参考文献 特開 昭60−172280(JP,A) 特開 昭54−76886(JP,A) 特開 平5−292943(JP,A) (58)調査した分野(Int.Cl.7,DB名) C12N 1/20 JSTplusファイル(JOIS)─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI (C12N 1/20 C12R 1:01) (72) Inventor Sayuri Miyaura 5-83 Higashihara, Zama City, Kanagawa Prefecture Mori Naga Milk Industry Co., Ltd. (56) References JP 60-172280 (JP, A) JP 54-76886 (JP, A) JP 5-292943 (JP, A) (58) Fields investigated ( Int.Cl. 7 , DB name) C12N 1/20 JST plus file (JOIS)

Claims (9)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 微生物を凍結又は凍結乾燥時の損傷から
保護する組成物であって、アスパラギン酸、アルギニ
ン、グルタミン酸、プロリン、リジン、ロイシン及びメ
チオニンからなる特定のアミノ酸群より選択される少く
とも3種のアミノ酸の混合物又はそれらの誘導体の混合
からなることを特徴とする微生物保護剤。
1. A composition for protecting microorganisms against damage during freezing or lyophilization, which is selected from at least 3 amino acids selected from the group consisting of aspartic acid, arginine, glutamic acid, proline, lysine, leucine and methionine. microbial protection agent characterized by comprising a mixture or mixtures of their derivatives species acids.
【請求項2】 3種のアミノ酸の混合物が、アスパラギ
ン酸、グルタミン酸及びリジンの混合物である請求項1
に記載の微生物保護剤。
2. The mixture of three amino acids is a mixture of aspartic acid, glutamic acid and lysine.
The microbial protectant according to.
【請求項3】 3種のアミノ酸誘導体の混合物が、アス
パラギン酸ナトリウム、グルタミン酸ナトリウム及びリ
ジン塩酸塩の等量混合物である請求項1に記載の微生物
保護剤。
3. The agent for protecting microorganisms according to claim 1, wherein the mixture of three kinds of amino acid derivatives is a mixture of equal amounts of sodium aspartate, sodium glutamate and lysine hydrochloride.
【請求項4】 微生物が、ビフィドバクテリウム(Bifi
dobacterium)属に属する微生物、ラクトバシラス(Lact
obacillus)属に属する微生物、ストレプトコッカス(Str
eptococcus) 属に属する微生物、ラクトコッカス(Lacto
coccus) 属に属する微生物、エンテロコッカス(Enteroc
occus)属に属する微生物又はこれらの混合微生物である
請求項1乃至請求項3に記載の微生物保護剤。
4. The microorganism is Bifidobacterium (Bifi)
Lactobacillus, a microorganism belonging to the genus dobacterium
bacterium belonging to the genus obacillus, Streptococcus (Str
Lactococcus (Lacto), a microorganism belonging to the genus eptococcus
Enterococcus (Enterococcus), a microorganism belonging to the genus coccus
The microorganism protecting agent according to claim 1, which is a microorganism belonging to the genus occus) or a mixed microorganism thereof.
【請求項5】 洗浄した湿菌体を水に分散した微生物の
菌体分散液に、アスパラギン酸、アルギニン、グルタミ
ン酸、プロリン、リジン、ロイシン及びメチオニンから
なる特定のアミノ酸群より選択される少くとも3種のア
ミノ酸の混合物又はそれらの誘導体の混合物を、アミノ
酸の総量として少なくとも0.5%(重量)の濃度で添
加して混合し、凍結又は凍結乾燥することを特徴とする
凍結又は凍結乾燥微生物の製造法。
5. A microbe prepared by dispersing washed wet cells in water .
In the bacterial cell dispersion, a mixture of at least three kinds of amino acids selected from a specific amino acid group consisting of aspartic acid, arginine, glutamic acid, proline, lysine, leucine and methionine, or a mixture of their derivatives is used as the total amount of amino acids. A method for producing a frozen or freeze-dried microorganism, which comprises adding at a concentration of at least 0.5% (by weight), mixing, and freezing or freeze-drying.
【請求項6】 アミノ酸の総量が、2〜20%(重量)
である請求項5に記載の凍結又は凍結乾燥微生物の製造
法。
6. The total amount of amino acids is 2 to 20% (by weight).
The method for producing a frozen or freeze-dried microorganism according to claim 5, wherein
【請求項7】 3種のアミノ酸の混合物が、アスパラギ
ン酸、グルタミン酸及びリジンの混合物である請求項5
又は請求項6に記載の凍結又は凍結乾燥微生物の製造
法。
7. The mixture of three amino acids is a mixture of aspartic acid, glutamic acid and lysine.
Alternatively, the method for producing a frozen or freeze-dried microorganism according to claim 6.
【請求項8】 3種のアミノ酸誘導体の混合物が、アス
パラギン酸ナトリウム、グルタミン酸ナトリウム及びリ
ジン塩酸塩の等量混合物である請求項5又は請求項6に
記載の凍結又は凍結乾燥微生物の製造法。
8. The method for producing a frozen or freeze-dried microorganism according to claim 5 or 6, wherein the mixture of the three kinds of amino acid derivatives is an equal mixture of sodium aspartate, sodium glutamate and lysine hydrochloride.
【請求項9】 微生物が、ビフィドバクテリウム(Bifi
dobacterium )属に属する微生物又はラクトバシラス
(Lactobacillus )属に属する微生物、ストレプトコッ
カス(Streptococcus)属に属する微生物、ラクトコッカ
ス(Lactococcus) 属に属する微生物、エンテロコッカス
(Enterococcus)属に属する微生物又はこれらの混合微生
物である請求項5乃至請求項8に記載の凍結又は凍結乾
燥微生物の製造法。
9. The microorganism is Bifidobacterium (Bifi).
microorganisms belonging to the genus dobacterium), microorganisms belonging to the genus Lactobacillus, microorganisms belonging to the genus Streptococcus, microorganisms belonging to the genus Lactococcus, enterococcus
The method for producing a frozen or lyophilized microorganism according to claim 5, which is a microorganism belonging to the genus (Enterococcus) or a mixed microorganism thereof.
JP03604295A 1995-02-01 1995-02-01 Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent Expired - Fee Related JP3504365B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP03604295A JP3504365B2 (en) 1995-02-01 1995-02-01 Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP03604295A JP3504365B2 (en) 1995-02-01 1995-02-01 Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent

Publications (2)

Publication Number Publication Date
JPH08205857A JPH08205857A (en) 1996-08-13
JP3504365B2 true JP3504365B2 (en) 2004-03-08

Family

ID=12458661

Family Applications (1)

Application Number Title Priority Date Filing Date
JP03604295A Expired - Fee Related JP3504365B2 (en) 1995-02-01 1995-02-01 Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent

Country Status (1)

Country Link
JP (1) JP3504365B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073752A1 (en) * 2015-10-30 2017-05-04 株式会社ヤクルト本社 Method for producing dried microbial cells

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106806A1 (en) * 2005-03-30 2006-10-12 Kyowa Hakko Kogyo Co., Ltd. Method for improvement of storage stability of dried microorganism
FR2903574B1 (en) * 2006-07-13 2008-09-05 Gervais Danone Sa CYSTEINE PELLETS AND THEIR USES AS BIFIDOBACTERIUM ANIMALIS LACTIS GROWTH ACTIVATORS.
KR101605516B1 (en) * 2015-06-11 2016-03-23 주식회사 종근당바이오 Method for Increasing Viability, Storage Stability, Acid Tolerance or Oxgall Tolerance of Lactic Acid Bacteria
EP3317395B1 (en) 2015-06-30 2020-07-15 Société des Produits Nestlé S.A. Composition suitable for protecting microorganisms
JP2023179810A (en) * 2020-11-13 2023-12-20 味の素株式会社 Viable microbial agent containing lactococcus lactis, microbe belonging to genus lactobacillus or mixed microbe thereof, and method for producing the same

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017073752A1 (en) * 2015-10-30 2017-05-04 株式会社ヤクルト本社 Method for producing dried microbial cells
JPWO2017073752A1 (en) * 2015-10-30 2018-08-16 株式会社ヤクルト本社 Method for producing dried microorganism cells
EP3369805B1 (en) 2015-10-30 2020-08-26 Kabushiki Kaisha Yakult Honsha Method for producing dried microbial cells
US10844347B2 (en) 2015-10-30 2020-11-24 Kabushiki Kaisha Yakult Honsha Method for producing dried microbial cells
EA039591B1 (en) * 2015-10-30 2022-02-15 Кабусики Кайся Якулт Хонса Method for producing dried microbial cells

Also Published As

Publication number Publication date
JPH08205857A (en) 1996-08-13

Similar Documents

Publication Publication Date Title
US4205132A (en) Lyophilization of bacteria
TURGAY et al. Isolation and characterization of Lactobacillus bulgaricus and Lactobacillus casei from various foods
US3897307A (en) Stabilized dry cultures of lactic acid-producing bacteria
US9848615B2 (en) Storage stable frozen lactic acid bacteria culture
AU2011340474B2 (en) Starter culture compositions
KR101604633B1 (en) Medium composition for culturing lactic acid bacteria and producing method of powder of lactic acid bacteria using the same
EP0259739A1 (en) Improved stability of freeze-dried cultures
CN103189499A (en) Agent for improvement in survival of lactic acid bacterium and/or bifidobacterium
KR102290654B1 (en) Cryoprotectant compositions and lactic acid bacteria preparations comprising the same
Daba et al. Detection of bacteriocin-producing lactic acid bacteria from milk in various farms in north-east Algeria by a new procedure.
Béal et al. Freezing of probiotic bacteria
Vegarud et al. Autolysis of group N streptococci. Effects of media composition modifications and temperature
Smittle et al. Death of Lactobacillus bulgaricus resulting from liquid nitrogen freezing
Meera et al. Partial characterization and optimization of parameters for Bacteriocin production by Probiotic Lactic acid bacteria
EP0196593B1 (en) Process to preserve acid-producing bacteria and compositions produced thereby
CN112342172A (en) Lactic acid bacteria freeze-drying protective agent and preparation method and application thereof
JP3504365B2 (en) Microbial protective agent and method for producing frozen or lyophilized microorganism using the protective agent
KR100413335B1 (en) Lactococcus lactis BH5(KCCM-10275) which is produced antimicrobial peptide
Chen et al. Effects of sugar alcohol and proteins on the survival of Lactobacillus bulgaricus LB6 during freeze drying
Sharma et al. Standardization of lyophilization medium for Streptococcus thermophilus subjected to viability escalation on freeze drying
EP0137869B1 (en) Derived nisin producing microorganisms, method of production and use and products obtained thereby
JPH08187072A (en) Food preserving agent and production thereof
KR102384604B1 (en) Composition comprising low molecular weight collagen-peptide for Cryopreservation of probiotics-coated and a Method for Cryopreservation Using the Same
US4728516A (en) Method for the preservation of creamed cottage cheese
US5707843A (en) Lactose enzyme compositions and method

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20031204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20031210

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071219

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081219

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081219

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091219

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101219

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101219

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111219

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111219

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121219

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121219

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131219

Year of fee payment: 10

LAPS Cancellation because of no payment of annual fees